DOV 21947 hydrochloride
| Title | Journal |
|---|---|
| The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats. | European journal of pharmacology 20121015 |
| Differential BDNF responses of triple versus dual reuptake inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and prefrontal cortex. | Journal of molecular neuroscience : MN 20120901 |
| Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. | Synapse (New York, N.Y.) 20120501 |
| Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. | Journal of psychiatric research 20120101 |
| The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition. | Journal of psychopharmacology (Oxford, England) 20111001 |
| 1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors. | Bioorganic & medicinal chemistry 20110601 |
| The secrets of a successful clinical trial: compliance, compliance, and compliance. | Molecular interventions 20110401 |
| Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. | The international journal of neuropsychopharmacology 20110301 |
| The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats. | Pharmacology, biochemistry, and behavior 20110101 |
| The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties. | The Journal of pharmacology and experimental therapeutics 20101201 |
| The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. | European journal of pharmacology 20100510 |
| The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20081201 |
| The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. | The Journal of pharmacology and experimental therapeutics 20080301 |
| Triple reuptake inhibitors ('broad spectrum' antidepressants). | CNS & neurological disorders drug targets 20070401 |
| Stereocontrolled synthesis of trisubstituted cyclopropanes: expedient, atom-economical, asymmetric syntheses of (+)-Bicifadine and DOV21947. | Organic letters 20060817 |
| Preclinical and clinical pharmacology of DOV 216,303, a 'triple' reuptake inhibitor. | CNS drug reviews 20060101 |
| DOV 216,303, a 'triple' reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. | Journal of clinical pharmacology 20041201 |
| 'Broad spectrum' antidepressants: is more better for the treatment of depression? | Life sciences 20031107 |
| Antidepressant-like actions of DOV 21,947: a 'triple' reuptake inhibitor. | European journal of pharmacology 20030214 |